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Epstein-Barr Virus LMP2A
Drives B Cell Development and Survival
in the Absence of Normal B Cell Receptor Signals
EBV-associated malignancies including NPC and HD
(for review, Rickinson and Kieff, 1996).
LMP2A contains twelve hydrophobic membrane-span-
ning regions and aggregates in the plasma membrane
in characteristic patches (Longnecker and Kieff, 1990;
Robert G. Caldwell*, Joanna B. Wilson,²
Steven J. Anderson*, and Richard Longnecker*³
*Department of Microbiology-Immunology
Northwestern University Medical School
Chicago, Illinois 60611
²Division of Molecular Genetics Longnecker et al., 1991). The cytoplasmic amino termi-
nus of LMP2A contains eight tyrosine residues, includ-Institute of Biomedical and Life Sciences
University of Glasgow ing a consensus immunoreceptor tyrosine activation
motif (ITAM) domain (Longnecker and Kieff, 1990). TheGlasgow G11 6NU
United Kingdom LMP2A ITAM, when phosphorylated, constitutively binds
the Syk protein tyrosine kinase (Fruehling et al., 1996).
In addition, LMP2A binds specific Src family protein
tyrosine kinases and other cellular proteins (LongneckerSummary
et al., 1991; Burkhardt et al., 1992). In EBV-transformed
B cells grown in vitro, the LMP2A amino terminal cyto-Epstein-Barr virus (EBV) establishes a persistent la-
plasmic domain functions to block BCR signal transduc-tent infection in peripheral B lymphocytes in humans
tion, preventing normal calcium flux and the accumula-and is associated with a variety of malignancies and
tion of tyrosine-phosphorylated proteins following BCRproliferative disorders. Latent membrane protein 2A
cross-linking (Miller et al., 1994, 1995; Longnecker and(LMP2A) is one of only two viral proteins expressed in
Miller, 1996). Inasmuch as this signaling block preventslatently infected B lymphocytes in vivo. LMP2A blocks
the activation of lytic replication in EBV-transformedB cell receptor (BCR) signal transduction in vitro by
cells, a role for LMP2A in establishing or maintainingbinding the Syk and Lyn protein tyrosine kinases. To
latency in vivo has been proposed (Miller et al., 1994,analyze the significance of LMP2A expression in vivo,
1995; Longnecker and Miller, 1996). However, the rele-transgenic mice with B cell lineage expression of
vance of LMP2A expression in human peripheral B cellsLMP2A were generated. LMP2A expression results in
has been difficult to examine due to the paucity of EBVthe bypass of normal B lymphocyte developmental
latently infected peripheral B cells (Yao et al., 1985;checkpoints allowing immunoglobulin-negative cells
Lewin et al., 1987; Lam et al., 1991; Yao et al., 1991;to colonize peripheral lymphoid organs, indicating that
Miyashita et al., 1995). To analyze the significance ofLMP2A possesses a constitutive signaling activity in
LMP2A expression in vivo, transgenic mice with B cellnontransformed cells.
lineage expression of LMP2A were generated. LMP2A
expression results in the bypass of normal B lymphocyte
Introduction developmental checkpoints allowing immunoglobulin-
negative cells to colonize peripheral lymphoid organs,
Epstein-Barr virus (EBV) is a nearly ubiquitous human on- indicating that LMP2A possesses a constitutive signal-
cogenic herpesvirus associated with numerous prolifer- ing activity in nontransformed cells.
ative disorders, including Burkitt's lymphoma, Hodgkin's
disease (HD), AIDS-associated immunoblastic lymphoma, Results
oral hairy leukoplakia, and nasopharyngeal carcinoma
(NPC) (for review, Rickinson and Kieff, 1996). B lympho- Transgene Construction and Expression
cytes infected with EBV in vitro are immortalized and
The Em-LMP2A transgene was constructed by inserting
subsequently termed lymphoblastoid cell lines (LCLs).
chimeric genomic and cDNA LMP2A sequences down-
These EBV-transformed LCLs contain EBV episomes
stream of the immunoglobulin heavy chain promoter
and nine virus-encoded proteins. Six are EBV nuclear
and intronic enhancer (Em). Two independent transgenic
antigens (EBNAs), EBNA1, EBNA2, EBNA3A, EBNA3B,
lines, designated TgE and Tg7, were analyzed. Southern
EBNA3C, and EBNALP (for review, Kieff, 1996). Three
hybridization of LMP2A cDNA sequences to BamHI-
are the integral latent membrane proteins (LMPs), LMP1
digested genomic tail DNA identified a 2300 bp band
(Kieff, 1996), LMP2A, and LMP2B (for review, Kieff,
predicted from the transgene sequence (data not shown).
1996). In healthy individuals, EBV typically establishes
Both lines exhibited no gross developmental defects
a persistent latent infection in which the virus can be
and can survive for greater than 12 months in a barrier
detected in resting, nonproliferating peripheral B lym-
facility. LMP2A expression was detected in purified
phocytes (Miyashita et al., 1995, 1997). These latently
splenic B cells by immunoblot analysis (Figure 1A) and
infected cells express only two virally encoded genes,
in bone marrow cells by RT-PCR (Figure 1B).
namely LMP2A and EBNA1 (Qu and Rowe, 1992; Tierney
et al., 1994; Chen et al., 1995; Miyashita et al., 1997).
LMP2A Redirects B Cell DevelopmentFurther, LMP2A is expressed in tumor cells in several
To examine effects of LMP2A expression on peripheral
B cell populations, flow cytometric analysis for expres-
sion of CD19 and IgM was performed on splenic cells.³To whom correspondence should be addressed (e-mail: r-long
necker@nwu.edu). TgE and Tg7 splenic cells displayed unique alterations
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Figure 1. LMP2A Expression in Em-LMP2A Mice
(A) Immunoblot of LMP2A expression in trangenic spleen samples.
(B) RT-PCR analysis of LMP2A expression in mouse bone marrow
samples. cDNA was prepared from two independent bone marrow
samples of each mouse genotype indicated in the presence (1) or
absence (-) of reverse transcriptase. cDNA was subjected to PCR
using either LMP2A or beta-2 microglobulin (b2m)-specific primers.
The amplified LMP2A-specific PCR products were visualized using
32P radiolabeled oligonucleotide OL115. b2m-specific PCR products
were visualized by ethidium bromide staining and LMP2A immu-
noblots were performed as previously described (Fruehling et al., Figure 2. Analysis of B Lymphocytes in Em-LMP2A Mice by Flow
1996). Cytometry
Single cell suspensions of bone marrow (BM) and spleen (SP) sam-
ples were prepared and stained with the indicated antibodies. Plots
show representative data from at least three independent experi-in surface phenotypes when compared to nontransgenic
ments. Relative percentages of lymphocyte gated cells are indi-littermates. First, transgenic animals typically showed a
cated. Boxes delineating CD431 and CD432 staining cells werereduction in the proportion and total number of CD191
determined using RAG-12/2 bone marrow samples (Figure 4; Spano-
B cells in the spleen (Figure 2A; Table 1). Second, and poulou et al., 1994).
more strikingly, a high proportion of the CD191 cells in
the transgenic spleens were negative for surface IgM
(Figure 2A; Table 1). Such cells were virtually absent in CD19 and IgM expression in transgenic bone marrow
cells was similar to that seen in the spleen; namely,the spleens of nontransgenic littermates. To verify that
the CD191IgM2 cells were from the B lineage, flow cyto- fewer CD191 cells were detected, with an especially
dramatic reduction in the proportion of IgM1 cells com-metric analysis was performed on splenic samples from
transgenic and littermate control animals. Staining for pared to nontransgenic animals (Figure 2B; Table 1).
Similar to the control animals however, the majority ofCD3, pan-NK, or CD11b in combination with CD19 dem-
onstrated that no more than background levels of stain- CD191 cells in the transgenic bone marrow did not ex-
press CD43 (Figure 2C; Table 1). The presence of CD432ing were apparent for CD19 and each of the other mark-
ers (data not shown). Staining with B220 and CD19 B lineage cells lacking IgM expression in transgenic
bone marrow suggested a potential defect at the pre-Bindicated that all CD191 cells were also B2201 (data not
shown). These data indicate that the CD191IgM2 cells stage of development.
observed in transgenic animals are not due to ectopic
expression of LMP2A in non-B lineage cells resulting in LMP2A Selectively Blocks Immunoglobulin
Heavy Chain Rearrangementthe up-regulation of CD19. In addition, flow cytometric
analysis staining for CD4 and CD8 of both splenic and To determine if a defect in immunoglobulin gene re-
arrangement might underlie the failure of transgenicthymic cell populations indicated no developmental de-
fect in T lineage cells. In conclusion, these data suggest bone marrow cells to express IgM, we investigated the
status of the immunoglobulin heavy (H) and kappa lightthat LMP2A redirects B lymphocyte development in Em-
LMP2A mice allowing IgM2 B lineage cells to accumu- chain genes (K) by using a PCR assay to detect ordered
D-JH, V-DJH, and V-JK gene rearrangements (Schlissellate in the periphery.
To determine the stage at which B cell development et al., 1991). In genomic DNA from whole bone marrow
of nontransgenic littermates, D-JH and V-DJH, as wellwas altered in Em-LMP2A mice, bone marrow cells from
transgenic and nontransgenic animals were examined as V-JK gene rearrangements were detected (Figures
3A±3C). Although D-JH rearrangements in transgenicfor expression of CD19, IgM, and CD43. In normal bone
marrow, appropriate immunoglobulin heavy chain gene animals were detected at levels comparable to non-
transgenic littermates (Figure 3A), V-DJH rearrange-rearrangement and expression is required for transition
from a CD191CD431 pro±B to a CD191CD432 pre±B cell ments were absent or detected at greatly reduced levels
(Figure 3B). Surprisingly, transgenic V-JK gene rear-stage (Rolink and Melchers, 1991). Subsequent re-
arrangement of immunoglobulin light chain genes and rangements were detected at the same level in trans-
genic and nontransgenic animals (Figure 3C). Together,expression of both heavy and light chains at the cell
surface allows for transition to the CD191IgM1 immature these data indicate that LMP2A expression in precursor
B cells alters normal B cell development, perhaps byB cell stage (Rolink and Melchers, 1991). The pattern of
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Table 1. Analysis of LMP2A Transgenic Mice
Bone Marrow Spleen
Tg CD191/ CD191IgM2/ Tg CD191/ CD191IgM2/
Transgenic Line Control CD191 (%)a CD191 (%)b Control CD191 (%)a CD191 (%)b
Tg71 (n 5 6)c 68% (48%±75%) 80% (66%±89%) 43% (23%±60%) 21% (7%±42%)
Control (n 5 6)c Ðd 60% (50%±66%) Ðd 2% (1%±2%)
TgE1 (n 5 5)e 66% (53%±77%) 97% (96%±98%) 42% (14%±86%) 76% (69%±84%)
Control (n 5 6)e Ðd 59% (49%±65%) Ðd 5% (4%±7%)
TgE1RAG-12/2 (n 5 4)f 60% (45%±87%) 100%g 54% (22%±112%) 100%g
RAG-12/2 (n 5 3)f 30% (16%±35%) 100%g Ðh Ðh
Flow cytometric analysis was performed on bone marrow or splenic cell populations as described in the Experimental Procedures.
a Average reduction of CD191 cells in bone marrow or spleen of the transgenic lines was determined by dividing the total number of CD191
cells in the bone marrow or spleen of each transgenic by the total number of CD191 cells in the bone marrow or spleen of control animals.
b Average percent of CD191 cells that were IgM2 in the bone marrow or spleen of the indicated murine lines was determined by dividing the
CD191IgM2 cell number in each line by the total number of CD191IgM2 and CD191IgM1 cells.
c Three different litters each composed of two Tg7 transgenics and two littermate controls were analyzed and used to derive the average
value. The range of values is indicated in parentheses.
d Total CD191 cells in littermate control animals were set at 100%.
e Two different litters each composed of two TgE transgenics and two littermate controls and a third litter composed of one TgE transgenic
and two littermate controls were used in the analysis to derive the average value. The range of values is indicated in parentheses.
f Two different litters, each also used for the TgE analysis composed of two TgE-RAG-12/2 animals and one or two RAG-12/2 animals were
used in the analysis to derive the average value. The range of values is indicated in parentheses.
g All cells in the RAG-12/2 background are IgM2 due to the absence of rearrangement in the RAG-12/2 background.
h There are no splenic B cells except background levels in RAG-12/2 animals.
transmitting signals normally attributed to the pre-BCR. Transgenic Bone Marrow Cells Proliferate
in IL-7-Dependent Growth ConditionsSpecifically, appearance of CD432 bone marrow cells
that lack V-DJH rearrangements suggests that signals To determine if CD432 cells present in the transgenic
bone marrow samples demonstrated theexpected char-from LMP2A may shut off VH recombination in a prema-
ture enforcement of allelic exclusion, while concomi- acteristics of normal pre±B cells, we examined the ability
of these cells to respond to IL-7. Precursor B cell growthtantly allowing cells to progress to a CD432 stage.
in IL-7-containing media in the absence of stromal cell
contact requires progression beyond the CD431 stage,LMP2A Alters B Cell Development
in a RAG-Deficient Background a transition dependent upon immunoglobulin heavy
chain gene rearrangement and expression (Era et al.,To directly test the possibility that LMP2A could provide
developmental signals normally associated with expres- 1991; Spanopoulou et al., 1994). Bone marrow cells
from TgE1RAG-12/2, TgE1RAG-11/1, and nontransgenicsion of a functional heavy chain gene, namely transition
from the pro±B to the pre±B cell stage (Rolink and Mel- RAG-11/1 animals were cultured in vitro in IL-7-con-
taining methylcellulose media. After 7 days, the numberchers, 1991), we examined the effects of Em-LMP2A
transgene expression in a recombinase-deficient back- of colonies and total cells recovered from the three cul-
tures was similar (data not shown), indicating that cellsground. Recombinase activating gene 1 (RAG-1) null
animals are unable to rearrange immunoglobulin genes
and are characterized by a block in B cell development
at the CD431 pro±B stage (Mombaerts et al., 1992;
Spanopoulou et al., 1994). This block can be partially
overcome by transgene-dependent expression of a
functional heavy chain that allows B cell precursors to
progress to the CD432 stage (Spanopoulou et al., 1994).
TgE animals were bred to RAG-12/2 mice, and subse-
quent TgE1RAG-12/2 were identified by PCR analysis of
genomic tail DNA with specific oligonucleotide primers
(data not shown). Flow cytometric analysis of splenic
cells from TgE1RAG-12/2 animals identified significant
numbers of CD191 cells, a population absent in spleens
of nontransgenic RAG-12/2 animals (Figure 4A; Table 1).
Similarly, bone marrow of TgE1RAG-12/2 animals exhib-
Figure 3. Detection of Immunoglobulin Gene Rearrangements inited a dramatic increase in CD191 cells when compared
Em-LMP2A Bone Marrow Cellsto the nontransgenic RAG-12/2 littermates (Figure 4B;
PCR amplification and detection of D-JH (A), V-DJH (B), and V-JK (C)Table 1). Examination of CD43 expression in these bone
gene segments using 32P radiolabeled oligonucleotides as de-marrow samples revealed that unlike nontransgenic
scribed. (D) Amplification of RAG-1 DNA sequences were used as
RAG-12/2 littermates, TgE1RAG-12/2 bone marrow con- a positive control (C) of DNA content. Two transgenic and two non-
tained a large percentage of CD191 cells that did not transgenic wild-type (WT) littermate control bone marrow samples
were used for each genotype.express CD43 (Figure 4C; Table 2).
Immunity
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Figure 4. Analysis of B Lymphocytes in TgE 3 RAG-12/2 Animals
Single cell suspension of bone marrow and spleen cells from non-
transgenic RAG-12/2 and TgE1RAG-12/2 littermates were stained Figure 5. Analysis of Transgenic Cells Grown in IL-7-Supplemented
with the indicated antibodies and analyzed by flow cytometry as Methylcellulose Media
described in Figure 1. Plots show representative data from two
(A) LMP2A expression from IL-7-stimulated bone marrow cultures.independent experiments.
(B) Flow cytometry analysis of cells cultured in IL-7. Equivalent
numbers of IL-7 cultured cells were stained with CD19- and IgM-
specific antibodies and analyzed as in Figure 1. Plots show repre-from the transgenic animals were able to survive and
sentative data from two independent experiments.proliferate in response to IL-7. As previously reported
(Spanopoulou et al., 1994), nontransgenic RAG-12/2
cells did not proliferate under these conditions (data not
shown). LMP2A expression, detected by immunoblot of appropriately developing B lymphocytes, including
downmodulation of CD43 expression, appropriate re-analysis of cultured cells (Figure 5A), confirms that
transgenic cells survive the culture conditions. Flow cy- arrangement of kappa light chain genes, IL-7 respon-
siveness, and colonization of splenic environments,tometric analysis of IL-7 cultures showed that virtually
all cells from the three cultures were CD191 (Figure 5B). they are unable to rearrange functional immunoglobulin
heavy chain genes and subsequently do not express aHowever, whereas cultures from nontransgenic RAG-
11/1 littermates contained numerous IgM1 cells, such pre-BCR. As well as providing a developmental signal
that bypasses the requirement for heavy chain genecells were absent in TgE and TgE1RAG-12/2 cultures
(Figure 5B). Taken together, the in vivo and in vitro char- expression in bone marrow, LMP2A provides a survival
signal to progenitor and peripheral B cells as evidencedacteristics of the Em-LMP2A transgenic bone marrow
cells indicate that LMP2A can provide development sig- by the increase in CD191IgM2 cells in spleens of Em-
LMP2A transgenic mice. Most striking is that the Em-nals that mimic those initiating from an immunoglobulin
heavy chain in the context of the pre-BCR. LMP2A transgene allows receptorless B cells to mature
into CD432 cells in the bone marrow that are able to
colonize the spleen in a RAG-12/2 background.Discussion
Previous studies have shown that LMP2A forms tyro-
sine-phosphorylated aggregates in the plasma mem-B lymphocytes from mice bearing targeted deletions of
RAG-1, RAG-2, immunoglobulin heavy chain, or the Syk brane, associates with the Syk and Lyn protein tyrosine
kinases, and blocks BCR signal transduction in EBV-protein tyrosine kinase genes are unable to progress
from the pro-B to pre-B developmental stage (Kitamura transformed lymphocytes in vitro (Longnecker et al.,
1991; Burkhardt et al., 1992; Miller et al., 1994, 1995;et al., 1991; Mombaerts et al., 1992; Shinkai et al., 1992;
Cheng et al., 1995; Turneret al., 1995). In animals lacking Fruehling et al., 1996; Fruehling and Longnecker, 1997).
In these cells, the potential for LMP2A to mimic ratherperipheral immunoglobulin heavy chain gene expres-
sion by means of inducible Cre-loxp-mediated gene tar- than inactivate signal transduction pathways was not
appreciated, especially since LMP2A is nonessential forgeting, receptorless B lymphocytes are eliminated by
apoptosis (Lam et al., 1997). These experiments illus- EBV transformation (Longnecker et al., 1992, 1993a,
1993b). Data presented herein suggests that when ex-trate the necessity for competent BCR signaling in all
stages of B cell development, from early B cell ontogeny pressed in progenitor mouse B lymphocytes in vivo,
LMP2A can supersede the pre-BCR and redirect B cellto peripheral B cell maintenance. Surprisingly, B cells
lacking BCR expression are prominent in the bone mar- development. This observation may have importance in
EBV-associated malignancies. Although Reed-Stern-row and periphery of the Em-LMP2A transgenic mice.
Although these B cells exhibit many of the hallmarks berg cells in HD have been characterized as germinal
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center±derived B lineage cells, some of these cells con- cells infected with EBV in vitro are similar to bone mar-
row cells from Em-LMP2A transgenic mice, in that theytain somatic mutations resulting in the absence of sur-
face Ig expression, thereby indicating that these cells undergo D-JH but not V-DJH gene rearrangements and
hence do not express a functional BCR (Katamine et al.,do not require BCR signaling for survival (Kanzler et al.,
1996; Braeuninger et al., 1997). By mimicking signals 1984). Theoretically, once latently infected bone marrow
cells enter the periphery, constitutive signaling fromderived from the BCR, LMP2A may provide a signal that
would maintain these cells in the absence of a compe- LMP2A could provide a survival signal that would main-
tain these cells in the absence of competent BCR or thetent BCR. This may be an important first step in the
development of HD. requirement for BCR signal transduction. Alternatively,
the LMP2A survival signal may be important for EBV toThe role of LMP2A inEBV latency has been thesubject
of much conjecture as the message for LMP2A is readily gain access to or manipulate the memory B cell pool.
Whatever the site of EBV latency in the human host,detected in immune competent hosts with EBV latent
infections (Qu and Rowe, 1992; Tierney et al., 1994; peripheral B cells harboring the virus may undergo lytic
replication when trafficking to the oral epithelium therebyMiyashita et al., 1997). Studies in vitro have indicated
that LMP2A blocks normal BCR signal transduction, allowing shedding of virus to naive hosts. In infected
hosts, latent infection enables the virus to escape im-which prevents switch from latent to lytic replication
following BCR signal transduction by surface immuno- mune destruction, while periodic reactivation transfers
virus back to epithelial tissue where the virus replicates.globulin cross-linking (Miller et al., 1994, 1995). These
observations have led to the hypothesis that the role of Future characterization of B lymphocytes from the Em-
LMP2A transgenic mice will delineate the effects ofLMP2A in latent EBV infection is to prevent activation
of lytic EBV replication by immunoglobulin-mediated LMP2A on normal B cell biology and elucidate the mech-
anisms underlying the persistence of EBV in latentlysignal transduction (Miller et al., 1993, 1994; Longnecker
and Miller, 1996). This LMP2A function would be impor- infected humans.
tant in preventing lytic replication in latently infected
lymphocytes as they circulate in the peripheral blood, Experimental Procedures
bone marrow, or lymphatic tissues where they might
Miceencounter antigens, super antigens, or other ligands that
The Em-LMP2A sequences were constructed using the followingcould engage B cell receptors and activate EBV lytic
cloning procedures. The SalI±NdeI fragment of p(m/m)gpt (Gros-
replication. Data reported herein indicate another poten- schedl and Baltimore, 1985) containing the E m sequences was
tial function for LMP2A in vivo, namely that LMP2A blunt-end cloned into the SmaI±EcoRV sites of pBluescript KS (Stra-
would provide a constitutive survival signal in mature tagene). This construct retains the immunoglobulin heavy chain pro-
moter CAP site but has lost the associated initiation codon. ToB cells. This LMP2A-derived signal would obviate the
enhance transcriptional efficiency of the transgene, the SmaI±necessity for BCR-induced survival signals in EBV la-
EcoRV fragment from pSAM3.1 (Dush et al., 1985) containing thetently infected peripheral B cells (Lam et al., 1997).
first exon of the murine adenine phosphoribosyltransferase (APRT)
The site of EBV latency in immune competent human gene was cloned into the HindIII site directly downstream of the
hosts is not fully delineated. Latency is not maintained immunoglobulin heavy chain promoter CAP site using HindIII linkers,
by reinfection of circulating B lymphocytes in the oral thereby generating p162. This plasmid was cut in the 39 multiple
cloning site with ClaI and subsequently religated with a MunI±ClaIepithelium. Acyclovir, a nucleoside analog that can in-
linker to generate pRL202. Due to the large size of the genomichibit lytic replication in the oral epithelium, has no effect
LMP2A sequences, EBV sequences designed for this construct areon the number of latently infected B cells in the periph-
a hybrid of cDNA and genomic sequences such that the LMP2A
eral blood (Yao et al., 1989). Recent studies suggest Bal±AvaI genomic fragment containing exons 2 through 8 was
that in peripheral blood, EBV may reside in memory B cloned into the corresponding BalI±AvaI cDNA fragment in pLMP2A
lymphocytes that are CD191, CD232, B72, sIg1, and (Longnecker et al., 1991) to generate pRL192. The EcoRI fragment
of pRL192 containing the chimeric LMP2A sequences was clonedsIgD2 (Miyashita et al., 1995, 1997; Babcock et al., 1998)
into the MunI site of pRL202 to generate pRL209. The SacI±KpnIand express EBNA1 and LMP2A (Qu and Rowe, 1992;
fragment of pRL209 encompassing the immunoglobulin promoter/Tierney et al., 1994; Miyashita et al., 1997; Babcock et
enhancer sequences, the APRT intron, and the cDNA/genomic
al., 1998). Other potential sites of EBV latency may in- LMP2A sequences was purified and microinjected into B6XSJL F1
clude bone marrow, lymph nodes, or other lymphoid single cell fertilized eggs as described (Hogan et al., 1994). The Em-
organs, as EBV can be isolated from virtually any LMP2A transgenic animals were bred to C57BL/6 animals for more
than four generations as hemizygous animals at the Northwesternlymphoid tissue (for review, Rickinson and Kieff, 1996).
University Center for Experimental Animal Resources in accordanceIt is intriguing to speculate that bone marrow cells may
with university animal welfare guidelines. Wild-type C57BL/6 andprovide a reservoir for EBV-infected cells in humans.
RAG2/2 animals were obtained from Jackson Laboratories.
Engraftment of bone marrow cells can result in the loss
of the resident virus or the appearance of a new virus Mouse Tail DNA Southern Hybridization
strain from donor lymphocytes (Gratama et al., 1988). Mouse tail (1 cm) was digested overnight in tail lysis buffer (100 mM
Progenitor B cellsmay be infected by EBV when circulat- Tris [pH 8], 100 mM NaCl, 5 mM EDTA, 0.2% SDS, and 100 mg/ml
proteinase K) at 558C with occasional vortexing. The solution wasing B cells containing the virus traffic to bone marrow.
centrifuged to pellet the cellular debris. The resulting solution wasProgeny of latently infected bone marrow cells could
phenol/chloroform extracted, and genomic DNA was subsequentlygenerate the relatively stable number of EBV-infected
precipitated with absolute ethanol. Genomic DNA (10 mg) was di-
lymphocytes observed in peripheral blood of latently gested with BamHI restriction endonuclese, subjected to standard
infected individuals (Yao et al., 1985, 1991; Lewin et al., gel electrophoreis in 0.8% agarose, and transferred to Genescreen
1987; Lam et al., 1991; Miyashita et al., 1995). Interest- Plus (NEN Dupont) per manufacturer's description. A 1,958 bp
BamHI fragment from pLMP2A (Longnecker et al., 1991) encodingingly, human fetal liver and bone marrow precursor B
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the entire LMP2A cDNA sequence was isolated and utilized as an OL115 TTGCTCTTCGTGCTCTTCATGTCC,
OL116 GAAGAGTATGCCAGCGACAATCAG,a32P random-labeled probe for Southern blot hybridization as de-
scribed (Marchini et al., 1993). and OL121 GAGTTTCAGTGCTCGTTGAGTCAG.
Isolation and Flow Cytometry Staining of Primary Cells Methocellulose Culture
Bone marrow cells were flushed from femurs using cold staining 5 3 105 cells were plated in 3 ml Methocult M3630 methocellulose
buffer (10 mg/ml BSA, 13 PBS, 10 mM Hepes, and 0.1% NaAzide). media (Stem Cell Technologies) per manufacturer's instructions.
Spleens were dissociated between frosted slides in staining buffer After 7 days of culture, cells were counted, washed three times in
to prepare single cell suspensions. Red blood cells were lysed in staining media, and subjected to flow cytometry as described
red blood cell lysis buffer (Sigma). Approximately 2 3 106 cells were above, and LMP2A immunoblot analysis using rat monoclonal anti-
incubated in staining buffer with previously optimized concentra- body 14B7 as described (Fruehling et al., 1996).
tions of the indicated antibodies on ice for 15 min. Cells were washed
and analyzed by flow cytometry using a Becton-Dickson FACScan
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